SCHEMBL23356095

SCHEMBL23356095

Cc1n[nH]c2nc(Nc3cccc4c3CCC4)c(F)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NISCH Q9Y2I1 1/20 0.43
▸ EGFR P00533 1/20 0.40
▸ CCR4 P51679 1/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ KCNK2 O95069 1/20 0.38
▸ KCNK10 P57789 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ KCNK18 Q7Z418 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ ULK1 O75385 1/20 0.37
▸ ZAP70 P43403 1/20 0.37
▸ ALOX5 P09917 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ RXRA P19793 2/20 0.35
▸ RXRB P28702 2/20 0.35
▸ RXRG P48443 2/20 0.35
▸ PPARA Q07869 2/20 0.35
▸ PPARG P37231 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30791217 1.00 NISCH (0.43) NISCHEGFRCCR4MEN1KCNK2
SCHEMBL30791210 0.89 NISCH (0.42) NISCHEGFRCCR4MEN1KCNK2
SCHEMBL23356021 0.89 NISCH (0.42) NISCHEGFRCCR4MEN1KCNK2
SCHEMBL23356090 0.88 NISCH (0.42) NISCHEGFRCCR4MEN1KCNK2
SCHEMBL30791245 0.88 NISCH (0.42) NISCHEGFRCCR4MEN1KCNK2
SCHEMBL23356028 0.88 EGFR (0.46) NISCHEGFRCCR4MEN1KCNK2
SCHEMBL30791200 0.88 EGFR (0.46) NISCHEGFRCCR4MEN1KCNK2
SCHEMBL28516710 0.87 NISCH (0.41) NISCHEGFRCCR4MEN1KCNK2
SCHEMBL29874266 0.87 NISCH (0.41) NISCHEGFRCCR4MEN1KCNK2
SCHEMBL23356024 0.87 NISCH (0.40) NISCHEGFRCCR4MEN1KCNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583852-B2 Heterocycle derivative JW PHARMACEUTICAL CORPORATION (KR) 2026-03-24 — — US disclosed
CN-112313232-B Novel heterocyclic derivatives JW中外制药公司 2024-03-08 — — CN disclosed
US-20220259199-A1 NOVEL HETEROCYCLE DERIVATIVE JW PHARMACEUTICAL CORPORATION (KR) 2022-08-18 — — US disclosed
EP-3822270-A1 NOVEL HETEROCYCLE DERIVATIVE JW Pharmaceutical Corporation (KR) 2021-05-19 — — EP disclosed
CN-112313232-A Novel heterocyclic derivatives JW中外制药公司 2021-02-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583852-B2 Heterocycle derivative AR, SRD5A1, NR5A1 NISCH 2474/4885EGFR 787/4885CCR4 482/4885
US-20220259199-A1 NOVEL HETEROCYCLE DERIVATIVE AR, BRDT, NR5A1 NISCH 484/4885EGFR 1730/4885CCR4 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback